Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064376 · ClinicalTrials.gov registry record · Phase 2
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00064376: Completed Phase 2 study, sponsored by Cedars-Sinai Medical Center.
NCT00064376 is a Phase 2 study that has completed, run by Cedars-Sinai Medical Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064376, a Phase 2 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
Interventions
- DRUG paricalcitol
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-05 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00064376 record still lists
NCT00064376 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which paricalcitol is the first listed.
NCT00064376 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00064376 about?
NCT00064376 is a clinical study titled "Paricalcitol in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
What is the current status of trial NCT00064376?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-05. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00064376?
The interventions under investigation include: paricalcitol (DRUG).
Who is sponsoring clinical trial NCT00064376?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia